FWM
RYTM icon

Focused Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Focused Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-300
Closed -$13.8K – 809
2023
Q4 		$13.8K Hold
300
– – ﹤0.01% 494
2023
Q3 		$6.88K Hold
300
– – ﹤0.01% 595
2023
Q2 		$4.95K Hold
300
– – ﹤0.01% 668
2023
Q1 		$5.35K Hold
300
– – ﹤0.01% 655
2022
Q4 		$8.74K Sell
300
-1,700
-85% -$43.7K ﹤0.01% 543
2022
Q3 		$49K Buy
+2,000
New +$37.2K 0.01% 282

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Focused Wealth Management's RYTM Position: Q1 2024 in Review

Focused Wealth Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2024, closing a stake of 300 shares — an estimated $13.8K sold.

Focused Wealth Management first reported a position in RYTM in Q3 2022 and held it in 6 quarters. The position peaked at $49K in Q3 2022. 167 funds tracked by Wall St. Rank hold RYTM as of Q1 2024.

  • Focused Wealth Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 300 Rhythm Pharmaceuticals shares in Q1 2024, an estimated $13.8K.
  • Focused Wealth Management first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Focused Wealth Management's Rhythm Pharmaceuticals position peaked at $49K in Q3 2022.
  • 167 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.